BACKGROUND & AIMS: Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. The present study assessed the safety, pharmacokinetics, and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day multiple ascending dose study in patients with chronic HCV genotype 1 infection. METHODS:Four cohorts of treatment-naïve (TN) patients (100 mg q12 h, 100 mg q8 h, 200 mg q12 h, 200 mg q8 h) and one cohort of non-responders (NR) to prior pegylated interferon alfa-ribavirin treatment (300 mg q12 h) were investigated. RESULTS: Danoprevir was safe and well tolerated; adverse events were generally mild, transient and were not associated with treatment group or dose level. Danoprevir displayed a slightly more than proportional increase in exposure with increasing daily dose and was rapidly eliminated from the plasma compartment. Maximal decreases in HCV RNA were: -3.9 log(10)IU/ml and -3.2 log(10)IU/ml in TN receiving 200 mg q8 h and 200 mg q12 h, respectively. End of treatment viral decline in these two cohorts was within 0.1 log(10)IU/ml of the viral load nadir. HCV RNA reduction in NR was more modest than that observed in upper dose TN cohorts. The overall incidence of viral rebound was low (10/37) and was associated with the R155K substitution in NS3 regardless of the HCV subtype. CONCLUSIONS: Danoprevir was safe and well tolerated when administered for 14 days in patients with chronic HCV genotype 1 infection. Treatment resulted in sustained, multi-log(10) IU/ml reductions in HCV RNA in upper dose cohorts. These results support further clinical evaluation of danoprevir in patients with chronic HCV.
RCT Entities:
BACKGROUND & AIMS:Danoprevir is a potent and selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. The present study assessed the safety, pharmacokinetics, and antiviral activity of danoprevir in a randomized, placebo-controlled, 14-day multiple ascending dose study in patients with chronic HCV genotype 1 infection. METHODS: Four cohorts of treatment-naïve (TN) patients (100 mg q12 h, 100 mg q8 h, 200 mg q12 h, 200 mg q8 h) and one cohort of non-responders (NR) to prior pegylated interferon alfa-ribavirin treatment (300 mg q12 h) were investigated. RESULTS:Danoprevir was safe and well tolerated; adverse events were generally mild, transient and were not associated with treatment group or dose level. Danoprevir displayed a slightly more than proportional increase in exposure with increasing daily dose and was rapidly eliminated from the plasma compartment. Maximal decreases in HCV RNA were: -3.9 log(10)IU/ml and -3.2 log(10)IU/ml in TN receiving 200 mg q8 h and 200 mg q12 h, respectively. End of treatment viral decline in these two cohorts was within 0.1 log(10)IU/ml of the viral load nadir. HCV RNA reduction in NR was more modest than that observed in upper dose TN cohorts. The overall incidence of viral rebound was low (10/37) and was associated with the R155K substitution in NS3 regardless of the HCV subtype. CONCLUSIONS:Danoprevir was safe and well tolerated when administered for 14 days in patients with chronic HCV genotype 1 infection. Treatment resulted in sustained, multi-log(10) IU/ml reductions in HCV RNA in upper dose cohorts. These results support further clinical evaluation of danoprevir in patients with chronic HCV.
Authors: Micaela B Reddy; Peter N Morcos; Sophie Le Pogam; Ying Ou; Karl Frank; Thierry Lave; Patrick Smith Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191
Authors: Micaela B Reddy; Yuan Chen; Joshua O Haznedar; Jennifer Fretland; Steven Blotner; Patrick Smith; Jonathan Q Tran Journal: Clin Pharmacokinet Date: 2012-07-01 Impact factor: 6.447
Authors: Barbara J Brennan; Agnès Poirier; Sebastian Moreira; Peter N Morcos; Petra Goelzer; Renée Portmann; Jiney Asthappan; Christoph Funk; Patrick F Smith Journal: Clin Pharmacokinet Date: 2015-05 Impact factor: 6.447
Authors: Scott D Seiwert; Steven W Andrews; Yutong Jiang; Vladimir Serebryany; Hua Tan; Karl Kossen; P T Ravi Rajagopalan; Shawn Misialek; Sarah K Stevens; Antitsa Stoycheva; Jin Hong; Sharlene R Lim; Xiaoli Qin; Robert Rieger; Kevin R Condroski; Hailong Zhang; Mary Geck Do; Christine Lemieux; Gary P Hingorani; Dylan P Hartley; John A Josey; Lin Pan; Leonid Beigelman; Lawrence M Blatt Journal: Antimicrob Agents Chemother Date: 2008-09-29 Impact factor: 5.191
Authors: Nigel J Liverton; Steven S Carroll; Jillian Dimuzio; Christine Fandozzi; Donald J Graham; Daria Hazuda; M Katherine Holloway; Steven W Ludmerer; John A McCauley; Charles J McIntyre; David B Olsen; Michael T Rudd; Mark Stahlhut; Joseph P Vacca Journal: Antimicrob Agents Chemother Date: 2009-10-19 Impact factor: 5.191
Authors: Hadas Dvory-Sobol; Kelly A Wong; Karin S Ku; Andrew Bae; Eric J Lawitz; Phillip S Pang; Jeanette Harris; Michael D Miller; Hongmei Mo Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191